Frontline Obinutuzumab Recommended for EU Approval for Follicular Lymphoma

July 21, 2017 – The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of obinutuzumab in the frontline setting for the treatment of patients with follicular lymphoma, according to Roche, the manufacturer of the treatment. The positive opinion from the CHMP is specifically for use of obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance in … (leggi tutto)